* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.
What are Click-Formed Proteolysis-Targeting Chimeras (CLIPTACs)?
Click-formed proteolysis-targeting chimeras (CLIPTACs) represent a transformative strategy in PROTAC degradation technology development that addresses the fundamental cell permeability limitations of conventional proteolysis-targeting chimeras (PROTACs). Unlike traditional PROTACs — which are pre-assembled, high-molecular-weight (often 700–1,000 Da) bifunctional molecules combining an E3 ubiquitin ligase recruiting ligand, a linker, and a target protein ligand — CLIPTACs employ a precursor-based approach in which two smaller molecular fragments independently enter cells and undergo in situ bioorthogonal click chemistry to assemble a functional PROTAC molecule intracellularly.
The CLIPTAC strategy fundamentally reimagines how heterobifunctional degraders are delivered to cells. Rather than attempting to optimize the cell permeability of a single large molecule, CLIPTAC technology divides the degrader into two low-molecular-weight precursor fragments: one bearing a tetrazine (Tz) moiety conjugated to an E3 ligase-recruiting ligand, and the other bearing a trans-cyclooctene (TCO) moiety conjugated to a target protein ligand. Upon cellular entry, these two precursors undergo a rapid, catalyst-free inverse electron-demand Diels-Alder (IEDDA) cycloaddition to form the complete PROTAC structure within the cell, which subsequently recruits the E3 ligase to the target protein, triggering ubiquitination and proteasomal degradation.
BOC Sciences offers a comprehensive CLIPTAC technology development service platform that supports pharmaceutical, biotechnology, academic, and contract research organization (CRO) teams in designing, synthesizing, and validating CLIPTAC precursor pairs. Our integrated approach connects bioorthogonal chemistry, PROTAC design, linker engineering, cellular pharmacology, and degradation mechanism studies to help clients build CLIPTAC programs with rigorous design logic, clear validation data, and actionable structure-activity insights.
Services
BOC Sciences' Comprehensive CLIPTAC Technology Development Services
Target Protein Feasibility Assessment and Ligand Selection
The starting point of any CLIPTAC project is determining whether the intended target protein is suitable for click-assembled degradation and identifying a ligand with an appropriate derivatization site for TCO conjugation. BOC Sciences evaluates target protein characteristics, available ligand structures, structure-activity relationship (SAR) data, solvent-exposed derivatization vectors, binding affinity tolerance to chemical modification, and cellular degradation feasibility to help clients select the most promising target-ligand pair for CLIPTAC development.
Target protein degradability assessment: evaluation of target protein half-life, ubiquitination propensity, cellular localization, expression level, and predicted accessibility to the ubiquitin-proteasome system (UPS)
Ligand suitability evaluation: analysis of available target protein ligand structures, binding sites, solvent-exposed functional groups, and tolerance to TCO derivatization at candidate exit vectors
Binding affinity preservation strategy: identification of derivatization positions that minimize perturbation of ligand-target binding affinity, supported by molecular docking and SAR review
Cell line and model system recommendation: selection of cell models with appropriate target expression levels, proteasome activity, and baseline degradation pathway competence
E3 Ligase-Recruiting Precursor Design and Optimization
The E3 ligase-recruiting precursor is the tetrazine-bearing half of the CLIPTAC pair. It must maintain productive E3 ligase engagement, provide a solvent-accessible tetrazine group for intracellular click reaction, and retain favorable cell permeability. We support the design and optimization of Tz-modified E3 ligase ligands across multiple ligase systems, including cereblon (CRBN), von Hippel-Lindau (VHL), inhibitor of apoptosis protein (IAP), and mouse double minute 2 homolog (MDM2).
CRBN-based Tz-precursor design: derivatization of immunomodulatory imide drug (IMiD) scaffolds such as thalidomide, pomalidomide, and lenalidomide with tetrazine via optimized linker attachment points that preserve CRBN binding and ternary complex cooperativity
VHL-based Tz-precursor design: Tz-functionalization of VHL ligands using exit vectors informed by VHL–EloB–EloC crystal structures to maintain high-affinity VHL binding
IAP- and MDM2-based Tz-precursor options: design of Tz-modified IAP and MDM2 ligands for projects requiring alternative E3 ligase engagement or tissue-selective degradation profiles
Tz stability and reactivity profiling: evaluation of tetrazine stability in cell culture medium, intracellular half-life, and click reaction kinetics with TCO-modified partners
Click Handle Selection, Exit-Vector Design, and Linker Engineering
The success of a CLIPTAC program depends critically on how the bioorthogonal click handles and the linker architecture connecting each precursor's functional modules are designed. BOC Sciences provides systematic support across click handle selection, exit-vector analysis, and linker optimization to balance intracellular click reactivity, ternary complex geometry, and precursor permeability.
Bioorthogonal handle pair selection: evaluation of tetrazine–TCO (IEDDA), strain-promoted alkyne–azide cycloaddition (SPAAC), copper-catalyzed azide–alkyne cycloaddition (CuAAC), and other click chemistry pairs based on reaction kinetics, biocompatibility, and precursor stability requirements
Exit-vector identification: structural analysis of E3 ligase ligand and target protein ligand to identify solvent-exposed derivatization positions that permit linker attachment without disrupting protein binding
Linker length, flexibility, and polarity design: systematic variation of linker length (typically spanning 5–30 atoms), rigidity (alkyl, PEG, amide, triazole-containing, or semi-rigid motifs), and polarity to balance intracellular click efficiency with ternary complex formation
Click handle-linker spatial optimization: modulation of the distance between the click-reactive group and the ligand binding pharmacophore to minimize steric interference during intracellular assembly
Precursor physicochemical profiling: calculation and measurement of molecular weight, cLogP, topological polar surface area (tPSA), and hydrogen bond donor/acceptor counts to guide permeability optimization
CLIPTAC Synthesis and Pairwise Compatibility Screening
BOC Sciences synthesizes CLIPTAC precursor pairs with high chemical purity and characterizes their pairwise compatibility — including click reaction kinetics, product formation efficiency, and potential side reactions — before advancing to cellular studies. We support both the synthesis of individual precursors and the generation of precursor libraries for structure-activity relationship exploration.
Tz-precursor synthesis: multi-step synthesis of tetrazine-modified E3 ligase ligands with optimized linkers, including purification and characterization by nuclear magnetic resonance (NMR) spectroscopy and high-resolution mass spectrometry (HRMS)
TCO-precursor synthesis: synthesis of TCO-modified target protein ligands, with careful handling of TCO isomer stability and stereochemical integrity
Precursor library generation: parallel synthesis of precursor pairs with systematic linker variations to explore structure-assembly-degradation relationships
Cell-free click reaction monitoring: kinetic analysis of click reaction between Tz- and TCO-precursors in buffered solution, including reaction rate determination, product yield quantification, and identification of potential degradation byproducts
Pairwise compatibility matrix: systematic evaluation of precursor combinations to identify pairs with optimal click efficiency, minimal side reactions, and compatible physicochemical properties
Cellular Uptake, Precursor Stability, and Sequential Dosing Optimization
A key operational variable in CLIPTAC experiments is the sequential dosing strategy: precursors must be delivered to cells in a manner that maximizes intracellular co-localization and click assembly while minimizing extracellular pre-reaction or precursor degradation. We provide systematic cellular uptake and stability evaluation to define robust dosing protocols.
Precursor cellular permeability measurement: quantification of precursor uptake using liquid chromatography-mass spectrometry (LC-MS)-based intracellular concentration determination and permeability classification (e.g., parallel artificial membrane permeability assay, PAMPA)
Precursor metabolic stability: evaluation of precursor stability in cell culture medium, intracellular stability over relevant incubation time windows, and susceptibility to metabolic enzymes
Sequential dosing protocol development: optimization of precursor addition order, concentration ratios, pre-incubation times, and total incubation duration to achieve maximum intracellular click assembly and target degradation
Extracellular pre-reaction assessment: evaluation of whether precursors react prematurely in culture medium and quantification of extracellular click product formation
Washout and pulse-chase protocols: design of washout experiments to distinguish degradation kinetics driven by pre-formed versus continuously assembled CLIPTAC molecules
Intracellular CLIPTAC Formation and Target Degradation Validation
The definitive readout of a CLIPTAC program is whether intracellular click assembly leads to productive ternary complex formation and proteasome-dependent target protein degradation. BOC Sciences provides multi-layered validation workflows that confirm click-dependent degradation, establish mechanism of action, and quantify degradation efficiency.
Intracellular click reaction confirmation: use of fluorescent or mass-tagged precursors to confirm intracellular co-localization and click product formation by confocal microscopy, in situ click chemistry imaging, or LC-MS analysis of cell lysates
Target protein degradation quantification: Western blot and quantitative proteomics-based determination of target protein levels following CLIPTAC treatment, including DC50 (half-maximal degradation concentration) and Dmax (maximal degradation) values
Ternary complex formation analysis: evaluation of CLIPTAC-induced ternary complex formation using co-immunoprecipitation, time-resolved fluorescence resonance energy transfer (TR-FRET), or bead-based luminescent proximity assays
Proteasome and ubiquitination dependence: confirmation of proteasome-dependent degradation using proteasome inhibitors (e.g., MG132, carfilzomib, bortezomib) and detection of target protein polyubiquitination
Click-dependence control experiments: use of non-reactive precursor controls (e.g., methyl-capped tetrazine, non-TCO-modified target ligand, or individual precursor-only treatments) to verify that degradation requires intracellular click assembly
Degradation selectivity profiling: proteomics-based assessment of degradation selectivity to confirm that CLIPTAC-mediated degradation is restricted to the intended target
Click Modalities
CLIPTAC Development Services by Click Chemistry Modality
The choice of bioorthogonal click chemistry is a foundational decision in any CLIPTAC program, as it governs reaction kinetics, biocompatibility, precursor stability, and intracellular assembly efficiency. BOC Sciences offers CLIPTAC development services across a comprehensive range of click chemistry modalities, allowing clients to select the reaction pair best suited to their target biology, precursor properties, and experimental requirements.
Tetrazine Ligation-Based CLIPTAC Development
Tetrazine–TCO IEDDA cycloaddition is the most widely validated bioorthogonal reaction for CLIPTAC applications, offering exceptionally fast kinetics (second-order rate constants up to 106 M−1s−1), catalyst-free operation, and compatibility with the intracellular environment. BOC Sciences has extensive experience designing Tz- and TCO-modified precursors, optimizing tetrazine stability, managing TCO isomerization, and validating intracellular click efficiency. This platform supports the degradation of targets including bromodomain-containing protein 4 (BRD4), extracellular signal-regulated kinase 1/2 (ERK1/2), and other oncology-relevant proteins.
Strain-promoted alkyne-azide cycloaddition (SPAAC) offers a copper-free click chemistry alternative with moderate reaction rates, excellent biocompatibility, and well-characterized bioorthogonal reagents including bicyclo[6.1.0]nonyne (BCN), dibenzocyclooctyne (DBCO), and difluorinated cyclooctyne (DIFO). BOC Sciences supports SPAAC-based CLIPTAC design for projects where tetrazine-TCO reactivity is too fast, where slower assembly kinetics are desired for temporal control, or where azide/alkyne handle incorporation is synthetically more accessible for a given ligand scaffold.
BCN-, DBCO-, and DIFO-modified precursor design and synthesis
Azide-tagged E3 ligase or target protein ligand preparation
SPAAC reaction rate optimization for intracellular conditions
Comparison with tetrazine-based CLIPTAC performance
CuAAC-Based CLIPTAC Development
Copper-catalyzed azide-alkyne cycloaddition (CuAAC) is the classic click reaction, offering robust triazole-forming chemistry with well-established ligand and catalyst systems. While intracellular copper catalysis introduces additional biocompatibility considerations, CuAAC-based CLIPTAC strategies can be advantageous for in vitro biochemical assembly, cell-free validation, or applications where copper-chelating ligand systems can be optimized for intracellular compatibility. BOC Sciences evaluates CuAAC feasibility on a case-by-case basis, considering copper toxicity thresholds, ligand acceleration strategies, and intracellular copper delivery methods.
CuAAC-compatible precursor design with terminal alkyne and azide handles
Copper ligand system selection (THPTA, BTTAA, TBTA) for biocompatibility
Cell-free CLIPTAC assembly and biochemical validation
Intracellular CuAAC optimization with biocompatible copper sources
Thiol-Ene-Based CLIPTAC Development
Thiol-ene click chemistry — the radical-mediated or base-catalyzed addition of thiols to alkenes — offers a complementary bioorthogonal approach for CLIPTAC assembly. This reaction benefits from the natural abundance of thiol-containing biomolecules as potential conjugation handles and the stability of the resulting thioether linkage. BOC Sciences supports thiol-ene-based CLIPTAC design for research programs exploring alternative bioorthogonal modalities or seeking to leverage thiol-containing ligand fragments.
Thiol- and alkene-modified precursor pair design
Photo-initiated and base-catalyzed thiol-ene reaction optimization
Selectivity assessment against endogenous thiols
Thioether-linked CLIPTAC stability evaluation
Oxime Ligation-Based CLIPTAC Development
Oxime ligation — the chemoselective condensation of aminooxy groups with aldehydes or ketones — provides a bioorthogonal conjugation strategy with moderate reaction rates and hydrolytically stable oxime ether products. While oxime ligation kinetics are slower than tetrazine-TCO IEDDA, this modality may be suitable for CLIPTAC applications where slower, more sustained intracellular assembly is therapeutically desirable or where aldehyde/ketone handles can be introduced with minimal perturbation to ligand pharmacology. BOC Sciences evaluates oxime ligation feasibility for appropriate CLIPTAC programs.
Aminooxy- and carbonyl-modified precursor synthesis
Oxime ligation rate optimization with aniline catalysis
Intracellular oxime bond stability assessment
Comparison of oxime-ligated CLIPTAC degradation efficiency with other click modalities
Hydrazone Ligation-Based CLIPTAC Development
Hydrazone ligation — the reaction of hydrazides or hydrazines with aldehydes or ketones to form hydrazone linkages — provides an additional bioorthogonal option for CLIPTAC assembly. Hydrazone bonds exhibit pH-dependent stability, which may offer unique opportunities for intracellular assembly in specific subcellular compartments with distinct pH environments. BOC Sciences supports hydrazone-based CLIPTAC design as a specialized modality within our broader click chemistry toolbox, with careful attention to hydrazone stability and intracellular reaction efficiency.
Hydrazide- and carbonyl-modified precursor design and synthesis
pH-dependent hydrazone formation and stability profiling
CLIPTAC development sits at the intersection of bioorthogonal chemistry, PROTAC design, and cellular pharmacology — three disciplines that must be integrated coherently for a program to succeed. BOC Sciences provides systematic solutions to the most common and consequential challenges encountered during CLIPTAC development, helping clients move from concept to validated degradation data with greater efficiency.
Balancing Precursor Permeability with Click Reactivity
A frequent tension in CLIPTAC design is that precursor properties favoring cell permeability (low polarity, moderate lipophilicity, compact structure) can conflict with those needed for efficient intracellular click reactivity (adequate linker length, solvent-exposed click handles). We address this through iterative design cycles where linker polarity, length, and click handle placement are varied while monitoring both permeability (via PAMPA or Caco-2 assays) and click kinetics (via cell-free and intracellular reaction monitoring). This integrated approach identifies design windows where both properties are simultaneously acceptable.
Preventing Premature Reaction and Nonspecific Conjugation
Tetrazine-TCO reactions can occur in culture medium if both precursors are present simultaneously, producing extracellular CLIPTAC that cannot cross the cell membrane. Our solution includes evaluating precursor stability in medium, designing sequential or staggered dosing protocols, and incorporating steric shielding strategies around click handles to reduce premature reactivity. We also assess whether click handles undergo nonspecific conjugation with endogenous biomolecules and modify handle chemistry or linker architecture accordingly.
Optimizing Precursor Ratio, Dosing Order, and Incubation Window
The intracellular concentration ratio of Tz- to TCO-precursors critically influences click product formation efficiency. We systematically evaluate precursor concentration matrices, addition sequences (e.g., TCO-precursor pre-loading followed by Tz-precursor addition, versus simultaneous co-treatment), and incubation time courses to identify conditions that maximize intracellular CLIPTAC assembly and target degradation while minimizing precursor consumption and off-target effects.
Improving Productive Ternary Complex Formation
Even when intracellular click assembly is confirmed, the resulting CLIPTAC molecule may not form a productive ternary complex if the linker connecting the two liganded protein surfaces is too short, too long, or too rigid. We address this by generating linker-length series (e.g., varying from 5 to 30 atoms) across different linker chemistries (PEG, alkyl, semi-rigid, triazole-containing) and evaluating ternary complex formation using TR-FRET or co-immunoprecipitation. This identifies linker geometries that support simultaneous E3 ligase and target protein engagement.
Distinguishing Click-Dependent Degradation from Precursor Effects
Individual CLIPTAC precursors — particularly the target protein ligand-TCO conjugate — may exhibit intrinsic biological activity, target engagement, or cytotoxicity independent of click assembly. Our validation strategy incorporates rigorous control experiments: (1) individual precursor treatment alone, (2) non-reactive Tz analog (e.g., methyl-capped tetrazine) co-treatment, (3) pre-formed CLIPTAC (cell-impermeable) as a negative control, and (4) proteasome inhibitor rescue. This control matrix unambiguously attributes degradation to intracellular click assembly.
Connecting Molecular Design with Cellular Degradation Outcomes
CLIPTAC datasets span chemistry (linker structure, click handle type, precursor logP), cell biology (uptake, stability, assembly efficiency), and pharmacology (ternary complex formation, degradation potency, selectivity). We integrate these data layers to generate structure-assembly-degradation relationship maps that reveal which molecular features drive cellular performance. This enables rational decision-making about whether to optimize the E3 ligand, target ligand, linker, click handle, dosing protocol, or cell model — rather than relying on trial and error.
Advance Your Targeted Protein Degradation Program with CLIPTAC Technology
From target feasibility assessment and precursor design through click chemistry optimization, intracellular assembly validation, and degradation profiling, BOC Sciences provides end-to-end CLIPTAC technology development support. Our integrated bioorthogonal chemistry and PROTAC expertise helps clients overcome the cell permeability barriers of conventional degraders and unlock new target space with click-assembled degradation strategies.
End-to-End CLIPTAC Technology Development Workflow
01
Project Definition and Target Feasibility Review
Define the target protein, review available ligand structures and SAR data, evaluate target degradability, assess cellular model suitability, and establish project goals, decision criteria, and desired data deliverables.
02
Precursor Pair Design and Synthetic Planning
Design Tz-modified E3 ligase ligand precursors and TCO-modified target protein ligand precursors, select exit vectors and linker architectures, plan synthetic routes, and prepare a precursor library design strategy.
03
Click Reaction Screening and Chemical Optimization
Synthesize precursor pairs, evaluate cell-free click reaction kinetics and product formation, optimize linker length and click handle placement, and confirm precursor chemical stability.
04
Cell-Based Assembly and Degradation Evaluation
Assess precursor cellular permeability and stability, optimize sequential dosing protocols, confirm intracellular click product formation, and quantify target protein degradation potency (DC50, Dmax).
05
Mechanism Confirmation and Selectivity Profiling
Validate proteasome and ubiquitination dependence, confirm ternary complex formation, perform click-dependence control experiments, and assess degradation selectivity through proteomics.
06
Iterative Optimization and Data Interpretation
Integrate structure-assembly-degradation data to refine precursor design, linker architecture, dosing protocol, or click chemistry modality. Deliver optimized precursor pairs, comprehensive data packages, and actionable recommendations for the next development stage.
Key Advantages of CLIPTAC Technology Over Conventional PROTACs
Significantly Improved Cell Permeability and Pharmacokinetics
Conventional PROTACs often have molecular weights of 800–1,000 Da and high polar surface areas, which can limit solubility, cellular uptake, and membrane penetration. CLIPTAC precursors are smaller, less polar fragments that enter cells independently via passive diffusion or active transport. This split-molecule strategy can improve intracellular exposure compared with the corresponding pre-assembled PROTAC.
Effective Mitigation of the Hook Effect
At high concentrations, conventional PROTACs may form excessive binary complexes instead of productive target–PROTAC–E3 ternary complexes, reducing degradation efficiency. CLIPTACs use separately delivered precursors that assemble inside cells. This in situ formation can reduce premature binding-site saturation and support productive degradation across a broader experimental concentration range.
Enhanced Targeting Precision and Reduced Off-Target Toxicity
Individual CLIPTAC precursors can be combined with tumor-homing ligands, nanoparticles, or tissue-directed delivery systems to promote local co-enrichment. Because the active degrader forms only after precursor co-localization and click assembly, exposure to the assembled molecule may be limited outside the intended site, helping reduce nonspecific protein degradation and off-target cellular effects.
Greater Flexibility in Research and Application
Conventional PROTAC programs often require extensive linker redesign for each target. CLIPTACs provide a modular alternative in which an E3 ligase-binding precursor can be paired with different target-binding precursors. This enables faster target-ligand exchange, streamlined degrader prototyping, and more efficient comparison of degradation strategies across multiple protein targets.
Applications
CLIPTAC Applications Across Drug Discovery Programs
Through modular precursor design and intracellular assembly, CLIPTAC technology offers a flexible approach to challenges involving permeability, spatial control, target validation, and resistance-related degrader redesign.
Tumor-Targeted Therapy
Conventional PROTACs for solid tumors may distribute into both tumor and normal tissues, limiting spatial selectivity. CLIPTAC precursors remain separate until click assembly and can be combined with tumor-targeting ligands, nanoparticle carriers, or other delivery strategies. Preferential precursor co-localization may support in situ degrader formation within the tumor environment while reducing exposure to the assembled PROTAC elsewhere.
Tumor-selective degradation through precursor targeting
Conventional PROTACs often have physicochemical properties that restrict blood-brain barrier (BBB) penetration. Smaller CLIPTAC precursors may be optimized independently for central nervous system (CNS) exposure and then assembled inside target cells. This strategy provides a research route for evaluating protein degradation against neurological targets that are difficult to address with pre-assembled bifunctional degraders.
Independent optimization of precursor BBB penetration
Conventional PROTAC development may require complete bifunctional-molecule redesign for each target. CLIPTACs use modular target-binding and E3 ligase-binding precursors, allowing one component to be retained while the other is exchanged. This approach can accelerate degrader prototyping, parallel target comparison, and early assessment of whether a protein is suitable for induced degradation.
Mutations within target-binding sites can reduce the activity of inhibitors and degraders. In a modular CLIPTAC system, the target-binding precursor can be replaced with a ligand that recognizes the resistant variant while retaining the E3 ligase module and click reaction pair. This enables faster construction and comparison of degraders against wild-type and mutant proteins.
Rapid ligand exchange for resistant target variants
Client Success Stories: CLIPTAC Technology Development
Project Background
A pharmaceutical discovery team sought to evaluate whether a CLIPTAC approach could achieve BRD4 degradation in HeLa cells with improved permeability relative to a pre-assembled PROTAC comparator (dBET1, MW = 785 Da). The client had a JQ1-based BRD4 ligand with a known solvent-exposed carboxylate suitable for derivatization but lacked experience with tetrazine-TCO click chemistry and intracellular assembly validation. Their primary goal was to establish proof-of-concept that a two-precursor CLIPTAC system could achieve comparable or superior BRD4 degradation relative to the conventional PROTAC, while demonstrating clear click-dependence.
Our Support
We designed two precursor series: (1) a Tz-thalidomide E3 ligase precursor series based on the published Tz-CRBN ligand scaffold, with three linker variants (5-, 9-, and 13-atom PEG linkers) to explore spatial accessibility of the tetrazine group, and (2) a JQ1-TCO target ligand precursor series where the JQ1 carboxylate was derivatized with TCO via carbamate-linked 3- and 6-carbon spacers. In total, we synthesized six precursor pairs (3 Tz-CRBN variants × 2 JQ1-TCO variants). Cell-free click kinetics confirmed rapid product formation (t1/2 < 15 min at 10 µM) for all pairs. We then evaluated intracellular BRD4 degradation in HeLa cells using a staggered dosing protocol: JQ1-TCO precursor pre-incubation (4 h, 1 µM), followed by Tz-thalidomide addition (1 µM, 20 h). Among the six pairs, the combination of the 9-atom PEG Tz-CRBN precursor and the 3-carbon spacer JQ1-TCO precursor achieved the strongest BRD4 degradation (Dmax ≈ 85% at 24 h, DC50 ≈ 0.3 µM for JQ1-TCO). Critically, control experiments — including methyl-capped tetrazine, non-TCO JQ1, and individual precursor-only treatments — showed no significant BRD4 reduction, confirming click-dependent degradation. We also demonstrated that the pre-assembled JQ1-CLIPTAC molecule (MW ≈ 1,167 Da) applied directly to cells produced negligible BRD4 degradation, validating the permeability advantage of the precursor approach. The client received a fully characterized lead precursor pair, a detailed structure-assembly-degradation relationship summary, and a recommended optimization path for linker refinement.
Client Testimonial
BOC Sciences provided exactly what we needed: a systematic CLIPTAC design and validation workflow that gave us confidence in the click-dependent degradation mechanism. Their rigorous control experiments and structure-assembly-degradation data made it clear which precursor features drove performance, enabling us to prioritize our next round of optimization with a solid rationale.
Project Background
A biotechnology company had developed a potent and selective kinase inhibitor targeting a therapeutically relevant oncology kinase. The team wanted to explore whether a CLIPTAC approach could convert this inhibitor into a degradation-based modality, but they faced two challenges: (1) the inhibitor's binding site was deeply buried with no obvious solvent-exposed derivatization vector, and (2) initial attempts at TCO conjugation led to a >50-fold loss in binding affinity. The client needed help identifying a viable derivatization strategy and validating that intracellular click assembly could restore degradation-competent ternary complex formation.
Our Support
We first performed a detailed SAR analysis and molecular docking study using the kinase-inhibitor co-crystal structure to identify candidate derivatization positions. Three solvent-accessible sites were evaluated: a solvent-exposed piperidine nitrogen, a meta-position on a pendant phenyl ring, and a terminal hydroxyl group on a flexible glycol chain. We synthesized TCO-modified analogs at each position (9 total precursors, including 3 linker lengths per position) and measured kinase binding affinity by TR-FRET. The glycol chain hydroxyl position with a 6-atom PEG linker preserved binding affinity within 3-fold of the parent inhibitor (Kd = 12 nM vs. 4 nM for parent), while the other positions caused >20-fold affinity loss. We then paired this optimized TCO-kinase ligand precursor with our Tz-CRBN precursor panel and evaluated degradation of the kinase target in the client's engineered cell line expressing a luminescent peptide-tagged kinase construct. Initial results showed modest degradation (Dmax ≈ 40%) with the standard 4 + 20 h dosing protocol. Suspecting that the kinase's nuclear localization was limiting cytoplasmic click assembly, we extended the TCO-precursor pre-incubation to 8 h and adjusted the Tz-precursor concentration from 1 to 3 µM. These changes improved Dmax to 72% with DC50 ≈ 0.5 µM. Proteasome inhibitor rescue (MG132) and non-reactive Tz controls confirmed a click- and proteasome-dependent mechanism. We also performed a pilot selectivity screen against 50 kinase targets, confirming that degradation was restricted to the intended kinase. The client received an optimized precursor pair, a validated dosing protocol, selectivity data, and a clear development path forward.
Client Testimonial
BOC Sciences' methodical approach to derivatization site identification and their willingness to troubleshoot our dosing protocol made the difference between a stalled project and a viable CLIPTAC lead. Their ability to integrate structural analysis, click chemistry, and cellular degradation data gave us a clear path from inhibitor to degrader.
Why Us
Why Partner with BOC Sciences for Your CLIPTAC Program?
Integrated PROTAC and Click Chemistry Expertise Under One Roof
Our teams connect target ligand chemistry, E3 ligase recruitment, linker design, bioorthogonal reaction development, protein ubiquitination, and cellular degradation evaluation without separating the project into disconnected workstreams.
Customizable CLIPTAC Design Platform with Rapid Iteration Cycles
Focused precursor matrices enable efficient comparison of exit vectors, click handles, E3 recruiters, and linker geometries. Results from each cycle are used to design the next small, information-rich analog set rather than expanding libraries without a defined hypothesis.
Comprehensive Bioorthogonal Chemistry Toolbox
We support tetrazine ligation, SPAAC, CuAAC-assisted studies, thiol–ene chemistry, oxime ligation, and hydrazone formation, with reaction-specific evaluation of kinetics, stability, competing chemistry, catalyst requirements, and biological compatibility.
Dedicated In-Cell Click Reaction and Degradation Profiling Capabilities
Intracellular assembled-product detection is analyzed together with precursor uptake, target degradation, ubiquitination, rescue experiments, and recovery kinetics. This provides a direct link between chemical conversion and biological outcome.
Flexible Collaboration for Different Project Stages
Clients can select a feasibility module, precursor design and synthesis, click-reaction screening, cell-based validation, or an integrated program. Existing client compounds and assays can be incorporated into the workflow where technically appropriate.
Data-Rich Deliverables with Actionable Structure-Activity Insights
Reports connect precursor structure, physicochemical properties, reaction behavior, intracellular exposure, assembled-product abundance, and degradation response. Clear decision points explain which component should be modified and why.
How do CLIPTACs improve intracellular degrader assembly?
CLIPTACs divide a conventional bifunctional PROTAC into a target-binding precursor and an E3 ligase-recruiting precursor. The two smaller components enter cells separately and subsequently undergo a bioorthogonal reaction to generate the functional degrader in situ. This strategy can reduce the molecular-weight and polarity burden associated with a pre-assembled PROTAC. Its success, however, depends on precursor uptake, intracellular stability, subcellular distribution, reaction kinetics, and the ability of the assembled product to form a productive ternary complex.
Which click chemistry is best for CLIPTAC development?
Inverse electron-demand Diels–Alder ligation between tetrazine and trans-cyclooctene is the best-established reaction for CLIPTAC assembly because it is rapid, catalyst-free, and compatible with complex biological environments. Strain-promoted azide–alkyne cycloaddition provides a copper-free alternative, although its kinetics and bulky cyclooctyne handles require careful optimization. BOC Sciences evaluates reaction systems according to ligand structure, precursor stability, cellular compatibility, and the required assembly window rather than selecting a modality solely by its theoretical reaction rate.
How should CLIPTAC precursor dosing be optimized?
Dosing optimization should compare precursor ratios, addition sequences, pre-incubation periods, washout steps, and total treatment times. A common approach is to preload the target-binding precursor when it enters or localizes within cells more slowly, followed by addition of the complementary E3 ligase-recruiting precursor. BOC Sciences can combine concentration matrices, time-course studies, intracellular precursor measurements, medium-stability testing, and extracellular pre-reaction analysis to identify conditions that favor intracellular co-localization and assembly while limiting precursor consumption and nonspecific cellular effects.
How is click-dependent protein degradation experimentally confirmed?
A decrease in target-protein abundance alone is insufficient to establish a click-dependent mechanism. Appropriate studies include each precursor alone, non-reactive handle controls, ligand competition, proteasome-inhibitor rescue, ubiquitination analysis, and direct confirmation of intracellular assembled-product formation. BOC Sciences can integrate cell-lysate mass spectrometry, fluorescence imaging, Western blotting, quantitative proteomics, ternary-complex assays, and DC50/Dmax measurements to distinguish genuine click-dependent degradation from target inhibition, precursor-associated activity, or nonspecific cellular stress.
When should researchers consider CLIPTAC over conventional PROTACs?
CLIPTAC development may be considered when a pre-assembled PROTAC has limited cellular uptake because of its size, polarity, or conformational complexity, or when a program requires rapid exchange of target-binding ligands across several degrader concepts. It can also support research involving sequential dosing, spatial control, or intracellular assembly. CLIPTACs are not universal replacements for conventional PROTACs; suitable derivatization sites, compatible reaction handles, stable precursors, productive ternary-complex geometry, and adequate cellular entry of both components are still required.
Quick Inquiry
BOC Sciences Support
Please contact us with any specific requirements and we will get back to you as soon as possible.
We invite you to contact us at or through our contact form above for more information about our services and products.
Significantly Improved Cell Permeability and Pharmacokinetics
